VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

"2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the human diagnostics market and as reported previously we are in confidential discussions with more than ten companies. "We are at various stages of the process across our different pillars ranging from due diligence, to tech transfer, to evaluation of clinical samples, to term sheet negotiation, and contract finalization. I am delighted to see things moving through the funnel, albeit confidentially at ...